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Highlights 
 High-dose methylprednisolone for the treatment of MS may be associated with 
hepatic adverse events.  
 Hepatotoxic effect of high-dose methylprednisolone seems to be an idiosyncratic 
reaction. 
 Dexamethasone may be used in further treatment of MS relapses in such patients.  
 
 
 
Abstract 
 
The standard therapy of multiple sclerosis (MS) relapse is high-dose pulse corticosteroid 
therapy. Although commonly applied and usually well tolerated it may as well carry certain 
risks for people with MS, the more severe of them being hepatotoxicity. This report 
describes three cases of acute liver injury following pulse corticosteroid therapy with 
reference to other possible causative factors. Caution should be exercised when applying 
high-dose methylprednisolone given the potential liver related adverse events it may cause. 
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1. Introduction 
 
The standard therapy of multiple sclerosis (MS) relapse is high-dose pulse corticosteroid 
therapy. Although commonly applied and usually well tolerated it may as well carry certain 
risks for people with MS (pwMS). The most common patient-reported adverse events are 
change in taste, flushing, abdominal pain, sleep disturbances and behavioural changes, 
which can have a substantial impact on every-day activities (Jongen et al., 2016). Even more 
severe side effects may develop affecting the gastrointestinal, cardiovascular or central 
nervous system, however, these are usually associated with prolonged steroid application 
(Shacke et al., 2002). Recently, there have been several reports of pwMS developing 
hepatitis. The paper by Cacao et al. reports on five pwMS and autoimmune hepatitis (Cacao 
et al., 2018).  What is notable in this report is the fact that four out of five patients were 
treated with high-dose methylprednisolone before presenting with hepatitis, indicating that 
drug toxicity served as a trigger in, until then, asymptomatic autoimmune hepatitis. Another 
recent article described a patient treated for MS relapse developing a methylpredinsolone-
induced liver injury (Bresteau et al., 2018).  Both of the aforementioned papers performed 
literature searches revealing another 35 cases of MS and autoimmune hepatitis and 12 
cases of corticosteroid induced liver injuries in MS patients. We report on three additional 
cases of acute liver injury following pulse corticosteroid therapy.  
 
2. Case reports 
Patient 1. A 37-year old woman developed right optic neuritis in 2008 and was diagnosed 
with relapsing remitting multiple sclerosis (RRMS) in 2010. She was treated with interferon 
beta-1a 44 mcg subcutaneously since 2011. In 2012 and in January 2015 she received 
intravenous high-dose methylprednisolone pulse therapy (1 gram daily for 3 consecutive 
days) due to relapses. In February 2015 she developed nausea and epigastric pain with 
blood tests revealing hepatic lesion with AST of 1095 U/L (11-38) and ALT of 2259 U/L (10-
36) (Fig. 1). Serological and immunological studies were normal or negative, including anti-
HAV IgM, anti-Hbc, anti-Hbs, anti-Hbe, HbsAg, HbeAg, anti-HCV. EBV EBNA, EBV VCA IgG and 
CMV IgG were positive while EBV VCA IgM and CMV IgG were negative. Interferon was 
promptly discontinued with a gradual decrease in liver enzyme values. Liver biopsy was 
performed revealing centrilobular necrosis with some lymphocytic and eosinophilic 
infiltration compatible with toxic liver necrosis. She was diagnosed with toxic liver injury 
caused by interferon. On further follow-up liver enzymes returned to normal and the 
patient was started on alemtuzumab receiving the first cycle in September of 2015 and the 
second in September in 2016, both of the times with prophylactic intravenous high-dose 
methylprednisolone therapy (1 gram daily for 3 consecutive days). Three months after the 
last dose of alemtuzumab and steroids another increase in liver enzyme was noted with AST 
of 91 U/L (11-38) and ALT of 140 U/L (10-36) which again resolved spontaneously. Since 
then the patient has remained stable and has not received further corticosteroid therapy. 
Patient 2. A 46-year old woman was diagnosed with RRMS in March 2015 and was started 
on vitamin D drops, 3000 IU per day. She received intravenous high-dose 
methylprednisolone pulse therapy (1 gram daily for 3 consecutive days) due to relapse in 
May 2015. In June 2015 elevated liver enzymes were noted with AST of 74 U/L and ALT of 
395 U/L (Fig 2.). Serological studies were negative including anti-Hbc, anti-Hbs, HbsAg, anti-
HCV . EBV EBNA, EBV VCA IgG and CMV IgG were positive while EBV VCA IgM and CMV IgG 
were negative. Immunological studies revealed presence of smooth muscle antibody (SMA) 
with a titre of 1:160 (negative <1:20). Vitamin D was promptly discontinued and in the 
following weeks liver enzyme values returned to normal. In April 2016 she experienced a 
relapse and was treated with intravenous high-dose methylprednisolone therapy (1 gram 
daily for 3 consecutive days) and subsequently experienced elevation of liver enzymes, AST 
of 79 U/L and ALT of 134 U/L. Liver biopsy was performed revealing mild diffuse hepatic 
steatosis. Hepatic enzyme values gradually decreased and the patient was started on 
glatiramer acetat. She experienced another relapse and was treated with lower-dose 
intravenous dexamehasone pulse therapy (50 mg for 3 consecutive days) in December 2017 
with subsequent transient elevation in liver enzyme values, AST of 54 U/L and ALT of 85 U/L. 
Patient 3. A 44-year-old woman was diagnosed with RRMS in 2007. She received 
intravenous high-dose methylprednisolone therapy (1 gram daily for 3 consecutive days) 
due to MS relapse in December 2011. In March 2012 she developed jaundice with nausea 
and anorexia. Liver enzymes were elevated with ALT of 1340 U/L (Fig. 3). Serological and 
immunological studies were normal or negative, including anti-Hbc, anti-Hbs, HbsAg, anti-
HCV as well as EBV and CMV PCR. Liver biopsy demonstrated portoportal and portocentral 
necrosis with some lymphocytic infiltration compatible with toxic liver necrosis. Liver 
enzymes gradually decreased with no specific therapy. The patient was started on 
glatiramer acetate in 2013 but continued to experience disease activity. Due to further 
relapses she repeatedly received lower-dose intravenous dexamethasone pulse therapy (16 
mg for 5 consecutive days) without a significant increase in live enzyme values. She stopped 
glatiramer acetate and started natalizumab in 2015. She has since been neurologically stable 
and has not experienced further liver damage.  
 
3. Discussion 
The presented cases emphasize the potential toxic effect of high-dose methylpredinsolone 
treatment of MS relapses. The exact hepatotoxic effect of corticosteroids is not completely 
elucidated and is proposed to be an idiosyncratic reaction with a latency period of weeks to 
months (D'Agnolo and Drenth, 2013). Therefore, monitoring liver enzyme values in this 
period might be warranted to detect this rare but potentially perilous adverse event. 
Furthermore, patients 1 and 2 were, as well, on interferon and vitamin D therapy, 
respectively, and it is known that these drugs may cause liver injury which might have 
produced an add-on effect to methylprednisolone-induced hepatotoxicity. However, as 
patient 1 had been receiving interferon therapy for four years prior to development of 
hepatic symptoms we believe this to be mainly methylprednisolone-related. A subsequent 
more modest rise in liver enzymes following methylprednisolone after a switch from beta-
interferon to alemtuzumab suggests there may have been a synergistic hepatotoxic effect of 
methylprednisolone plus interferon beta. 
Pathological finding of liver biopsy from patient 1 has shown centrilobular necrosis, from 
patient 2 diffuse steatosis and from patient 3 portoportal and portocentral necrosis. All of 
this patterns have been described in drug-induced liver injury which further substantiates 
the diagnosis in the presented patients (Kleiner et al., 2014). Infectious hepatitis serology 
was negative in all of the patients and a thorough screening is mandatory in such cases as 
toxic hepatitis is mainly a diagnosis of exclusion.  
Another important aspect of this report is that two of the patients were treated with lower-
dose dexamethasone therapy for relapses after the initial episodes of liver injury causing a 
modest (Case2) or no rise in liver enzymes. Such cases of pwMS who experienced 
methylprednisolone-induced liver injury and were subsequently treated with 
dexamethasone for MS relapses have been described before and it appears to be a safe 
strategy to avoid repeated hepatic injury (D'Agnolo and Drenth, 2013). As well, 
dexamethasone’s efficacy was assessed in a small double-blind randomized study and has 
shown an effect comparable to high-dose methylprednisolone for treatment of MS relapses 
(Milanese et al.,1989).  
Finally, the case of patient 2 is significant for positive autoimmune hepatitis markers (SMA) 
and negative biopsy finding. On one hand, the biopsy results may represent false negative 
findings. However, the patient's symptoms resolved after withdrawal of corticosteroid 
therapy which led us to a conclusion that the liver injury was drug-induced and that the 
presence of SMA was an epiphenomenon given that a proportion of MS patients may have 
positive immunological tests without a clinical expression of another autoimmune disease 
(Adamec et al., 2012).  
In conclusion, although methylprednisolone represents standard therapy of acute 
neurological worsening in pwMS it needs to be applied with caution given the potential liver 
related adverse events it may cause.  
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Figures 
Figure 1. Graphical presentation of liver enzymes and steroid therapy in 3 presented 
patients.  
The y-axis representing liver enzyme values in U/L, AST in blue and ALT in red. The x-axis 
representing time frame of corticosteroid application and liver enzyme dynamics. The green 
squares representing point in time when intravenous methylprednisolone therapy was 
given. The orange squares representing point in time when intravenous dexamethasone 
therapy was given. The bold horizontal line representing the upper limit for liver enzyme 
reference values.  
 
 
